Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Teerlink, John; Diaz, Rafael; Felker, G.; McMurray, John; Metra, Marco; Solomon, Scott; Adams, Kirkwood; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John; Corbalan, Ramon; Crespo-Leiro, Maria; Dahlstrom, Ulf; Echeverria Correa, Luis; Fang, James; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen; Howlett, Jonathan; Lanfear, David; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin-ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan; YILMAZ, MEHMET; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason; Abbasi, Siddique; Varin, Claire; Malik, Fady; Kurtz, Christopher

doi:10.1002/ejhf.2015

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Teerlink J. R., Diaz R., Felker G. M., McMurray J. J. V., Metra M., Solomon S. D., ...Daha Fazla

EUROPEAN JOURNAL OF HEART FAILURE, cilt.22, sa.11, ss.2160-2171, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 11
Basım Tarihi: 2020
Doi Numarası: 10.1002/ejhf.2015
Dergi Adı: EUROPEAN JOURNAL OF HEART FAILURE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.2160-2171
Anahtar Kelimeler: Heart failure, Omecamtiv mecarbil, Cardiac myosin activator, Inotrope, Myotrope, Cardiovascular outcomes trial, CARDIAC MYOSIN ACTIVATOR, INCREASE CONTRACTILITY, TOLVAPTAN, MORTALITY, OUTCOMES, PHASE-2, WOMEN
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.